March 31, 2025 — Using intravascular imaging (IVI) to guide stent implantation during complex stenting procedures is safer and more effective for patients with severely calcified coronary artery disease than conventional angiography, the more commonly used technique.

March 29, 2025 — Anthos Therapeutics, Inc., presented two new analyses from its AZALEA-TIMI 71 study at the American College of Cardiology Annual Scientific Session (ACC.25) demonstrating the novel Factor XI inhibitor abelacimab significantly reduced bleeding in patients regardless of age or bleeding risk. 

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes.

March 31, 2025 —  iRhythm Technologies, Inc. has announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago.

March 31, 2025 — AGEPHA Pharma USA, LLC, has highlighted clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease.

Mar. 28, 2025 — At the American College of Cardiology (ACC) 2025 meeting, GE HealthCare will introduce Revolution Vibe,i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries.

March 27, 2025 — GE HealthCare is announcing the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the 2025 American College of Cardiology (ACC) Annual Scientific Session & Expo in Chicago. 

Flyrcado is a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent. 

March 27, 2025 — Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System within Abbott's PFA clinical studies. The company will further expand use of Volt in EU markets throughout the second half of 2025. 

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA (finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now